• Utilization of a 2000-node Coherent Ising Machine (CIM) achieves stable solutions for over an hour. • Resolves core challenges including allosteric site detection and peptide docking, demonstrating superior speed and accuracy over heuristic algorithms. • Efficacy of newly discovered compounds cross-validated through in vitro and in-cell assays, as well as crystal structures. [Quantum Biology Society] Quantum computing technology has presented a new breakthrough for the drug discovery process, which typically involves significant investments of time and resources. A revolutionary framework has been developed to support multi-stage drug design by leveraging quantum hardware to solve large-scale combinatorial optimization problems (COPs) frequently encountered in computer-aided drug discovery (CADD). According to recent academic reports, a study has been published demonstrating the application of a Coherent Ising Machine (CIM)—specialized in solving large-scale COPs—across an entire drug discovery pipeline. Despite their potential, earlier CIM implementations have struggled to sustain long-term stability, hindering their applications in compute-intensive tasks like CADD. The research team constructed a 2000-node, third-generation CIM named 'QBoson-CPQC-3Gen,' featuring improved fiber vibration isolation and temperature control systems. This system successfully overcame existing hardware limitations by achieving stable solutions over one hour on large-scale COPs. ■ Translating Biological Dilemmas into 'Quantum Language': Graph-Based Encoding A defining feature of this study is the establishment of an end-to-end framework capable of initiating from a disease protein and proceeding through a full drug-design pipeline. The researchers translated complex drug discovery problems into graph-based encoding schemes readable by the CIM. Through this approach, three core CADD tasks—allosteric site detection, protein-peptide docking, and intermolecular similarity calculation—were integrated into a unified quantum computing framework. ■ Demonstrating Search Speed and Accuracy that Outperform Existing Algorithms To overcome the limitations of conventional geometry-inspired local-search methods, the team reformulated allosteric site prediction as a global-search strategy to find the max-weighted clique within a graph. As a result, they identified two previously unreported binding sites on GALR1 and SIRT2 proteins, which are important targets for depression and aging, respectively. The framework also yielded remarkable results in peptide docking, which deals with flexible molecular conformations. Using a graph model weighted by binding energies, the team successfully derived novel peptide modulators acting on neurotensin receptor type 1 (NTSR1) and the APC-Asef protein-protein interaction, which is linked to colorectal cancer migration. Furthermore, intermolecular similarity calculations—essential for identifying "me-better" compounds—were resolved by converting the task into a maximum-weighted independent set (MWIS) problem that prevents invalid atom mappings. The CIM-based approach recorded overwhelming speedups, reducing computation time by one to five orders of magnitude compared to CPU-based heuristic algorithms. The research team rigorously validated the targets and compounds predicted by CIM computations through in vitro assays, in-cell experiments, and crystal structures. "This achievement is a perfect milestone demonstrating how quantum computing can pioneer real-world pharmaceutical research through concurrent advancements in both hardware and encoding methodologies," an industry expert commented. "It will dramatically accelerate the research and development (R&D) speed of platform biotech companies aiming to discover novel drug candidates and pursue out-licensing deals in the future."
• Utilization of a 2000-node Coherent Ising Machine (CIM) achieves stable solutions for over an hour. • Resolves core challenges including allosteric site detection and peptide docking, demonstrating superior speed and accuracy over heuristic algorithms. • Efficacy of newly discovered compounds cross-validated through in vitro and in-cell assays, as well as crystal structures. [Quantum Biology Society] Quantum computing technology has presented a new breakthrough for the drug discovery process, which typically involves significant investments of time and resources. A revolutionary framework has been developed to support multi-stage drug design by leveraging quantum hardware to solve large-scale combinatorial optimization problems (COPs) frequently encountered in computer-aided drug discovery (CADD). According to recent academic reports, a study has been published demonstrating the application of a Coherent Ising Machine (CIM)—specialized in solving large-scale COPs—across an entire drug discovery pipeline. Despite their potential, earlier CIM implementations have struggled to sustain long-term stability, hindering their applications in compute-intensive tasks like CADD. The research team constructed a 2000-node, third-generation CIM named 'QBoson-CPQC-3Gen,' featuring improved fiber vibration isolation and temperature control systems. This system successfully overcame existing hardware limitations by achieving stable solutions over one hour on large-scale COPs. ■ Translating Biological Dilemmas into 'Quantum Language': Graph-Based Encoding A defining feature of this study is the establishment of an end-to-end framework capable of initiating from a disease protein and proceeding through a full drug-design pipeline. The researchers translated complex drug discovery problems into graph-based encoding schemes readable by the CIM. Through this approach, three core CADD tasks—allosteric site detection, protein-peptide docking, and intermolecular similarity calculation—were integrated into a unified quantum computing framework. ■ Demonstrating Search Speed and Accuracy that Outperform Existing Algorithms To overcome the limitations of conventional geometry-inspired local-search methods, the team reformulated allosteric site prediction as a global-search strategy to find the max-weighted clique within a graph. As a result, they identified two previously unreported binding sites on GALR1 and SIRT2 proteins, which are important targets for depression and aging, respectively. The framework also yielded remarkable results in peptide docking, which deals with flexible molecular conformations. Using a graph model weighted by binding energies, the team successfully derived novel peptide modulators acting on neurotensin receptor type 1 (NTSR1) and the APC-Asef protein-protein interaction, which is linked to colorectal cancer migration. Furthermore, intermolecular similarity calculations—essential for identifying "me-better" compounds—were resolved by converting the task into a maximum-weighted independent set (MWIS) problem that prevents invalid atom mappings. The CIM-based approach recorded overwhelming speedups, reducing computation time by one to five orders of magnitude compared to CPU-based heuristic algorithms. The research team rigorously validated the targets and compounds predicted by CIM computations through in vitro assays, in-cell experiments, and crystal structures. "This achievement is a perfect milestone demonstrating how quantum computing can pioneer real-world pharmaceutical research through concurrent advancements in both hardware and encoding methodologies," an industry expert commented. "It will dramatically accelerate the research and development (R&D) speed of platform biotech companies aiming to discover novel drug candidates and pursue out-licensing deals in the future."
• Constructed an integrated multi-stage drug design framework utilizing QBoson-CPQC-3Gen, a 2000-node coherent Ising machine (CIM). • Demonstrated superior speed and accuracy over existing heuristic algorithms in core calculations, including allosteric site detection, protein-peptide docking, and intermolecular similarity calculation. • Successfully identified and validated 2 novel druggable sites and bioactive compounds for 6 targets. [Quantum Biology Society] A recent study that overcomes the massive time and computational costs of drug discovery through quantum computing has captured the attention of the pharmaceutical and biotechnology industries. On February 11th, a paper titled "Large-scale quantum computing framework enhances drug discovery in multiple stages" was posted on bioRxiv, a preprint repository for the biological sciences. ■ Stable Computation for Over an Hour... Solving the CADD Bottleneck Traditional computer-aided drug discovery (CADD) consumes astronomical computational costs and resources when processing large-scale combinatorial optimization problems (COPs). To resolve this bottleneck, the research team improved the fiber vibration isolation and temperature control systems to introduce "QBoson-CPQC-3Gen," a coherent Ising machine (CIM) equipped with 2000 nodes. This system showcased groundbreaking performance by achieving stable optimal solutions on large-scale problems for over one hour. Utilizing this improved CIM, they successfully constructed a graph-based quantum computing framework capable of simultaneously handling three major challenges in drug discovery: allosteric site detection, protein-peptide docking, and intermolecular similarity calculation. ■ Overwhelming Speed and Accuracy, Complete with Real-World Wet-Lab Validation The experimental results were highly successful. To solve optimization problems, the newly developed CIM-based methods demonstrated superior computational speed and enhanced accuracy compared to the heuristic algorithms traditionally used on classical computers. Most notably, this technology did not stop at mere theoretical simulations. By applying this system to actual pharmaceutical research, the team successfully identified 2 novel druggable sites and bioactive compounds for 6 targets. Furthermore, these predictive results were comprehensively cross-validated in vitro, in-cell, and by crystal structures. By proving that quantum computing can be integrated into the entire multi-stage drug design process, this research represents a significant advancement in both quantum computing applications and pharmaceutical research.
Coherent Ising machines (CIMs) excel at solving large-scale combinational optimization problems (COPs), but their insufficient long-term stability has hindered their applications in compute-intensive tasks like computer-aided drug discovery (CADD). By improving fiber vibration isolation and temperature control system, we have implemented a 2000-node CIM named QBoson-CPQC-3Gen achieving stable solutions over one hour on large-scale COPs. Graph-based encoding schemes were further introduced to realize a CIM-based CADD workflow including allosteric site detection, protein-peptide docking and intermolecular similarity calculation. CIM-based methods demonstrated superior speed and accuracy than heuristic algorithms. Especially, QBoson-CPQC-3Gen identified 2 novel druggable sites and bioactive compounds for 6 targets, which were further validated in vitro, in-cell and by crystal structures. Our contributions established a quantum-computing framework for multi-stage drug discovery, representing a significant advancement in both quantum computing applications and pharmaceutical research.
A study published on the preprint repository arXiv comprehensively outlines empirical applications of quantum algorithms (such as VQE, QAOA) that can be executed on near-term noisy intermediate-scale quantum (NISQ) hardware to solve key challenges in molecular biology and drug discovery, such as protein folding and molecular docking. Through quantum simulations that overcome the limits of classical computing, it was demonstrated that by directly simulating the Hamiltonian of a chemical system, the 3D energy-minimized state of peptides or small molecule compounds can be accurately predicted with significantly fewer computing resources than before. It provides a practical roadmap for combining quantum machine learning (QML) and molecular biology to dramatically reduce massive computational costs and achieve overwhelming efficiency in the next-generation in silico drug discovery process. [Quantum Biology Society] Problems such as protein folding and molecular docking, which cause the biggest bottlenecks in the drug discovery process, become exponentially more complex as the amino acid sequence gets longer. The number of cases to explore explodes, making it difficult for classical computers to handle their NP-hard complexity. Recently, a groundbreaking demonstration framework aiming to introduce the latest quantum computing algorithms into the pharmaceutical and biotechnology fields to overcome these limitations has been presented, drawing attention from the related industry. The paper titled "Quantum computing for molecular biology," published on the preprint repository arXiv, comprehensively covers the application of practical quantum algorithms (e.g., VQE, QAOA) capable of solving drug discovery challenges that have hit the limits of classical computing, using noisy intermediate-scale quantum (NISQ) hardware. A research team including Alberto Baiardi and Markus Reiher from ETH Zurich in Switzerland, along with Matthias Christandl from the University of Copenhagen in Denmark, led this innovative convergent research. ■ Quantum Simulation: Overcoming the Limits of Classical Computing The research team demonstrated that by utilizing the characteristic of quantum computers to efficiently map and directly simulate the Hamiltonian of chemical systems, the complex 3D energy-minimized states of peptides or small molecule compounds can be accurately found with significantly fewer computing resources than before. This is because quantum computers can fundamentally bypass the "curse of dimensionality," where the computational amount expands exponentially, by naturally simulating the quantum mechanical properties of molecules. ■ A Roadmap for Next-Generation Drug Discovery This research goes beyond simply presenting algorithms; it provides a specific roadmap for next-generation in silico drug discovery processes by combining quantum machine learning (QML) and molecular biology. Through this, it has opened a path to achieve overwhelming efficiency by drastically reducing the massive computational costs and time required to screen drug candidates and optimize their most stable binding structures. This practical guide strongly suggests that quantum computing will become a core foundational technology bringing substantial innovation to the life sciences and pharmaceutical industries in the future. https://arxiv.org/abs/2212.12220
A study published in the Journal of Computer-Aided Molecular Design presents the first innovative quantum algorithm for identifying the optimal docking sites where proteins and ligands bind during the drug design process. It expands the existing protein lattice model to fully include hydrogen bonding and hydrophobic interactions, introducing quantum state labelling for interaction sites and applying an extended and modified Grover quantum search algorithm. The algorithm was successfully verified on IBM's real 127-qubit quantum computers by applying error mitigation techniques (such as M3 and Pauli twirling), and it is expected to exponentially accelerate drug candidate screening for large proteins as hardware scales up in the future. [Quantum Biology Society] Even after the introduction of High-Performance Computers (HPC) into drug development, protein-ligand docking has faced fundamental computational limits with classical computing methods because it is inherently a complex quantum mechanical interaction process. In response to the question, "Can quantum computers be used in drug design and how?" raised alongside the rapid advancement of quantum computers today, a study titled "Quantum algorithm for protein-ligand docking sites identification in the interaction space," recently published in the international journal Journal of Computer-Aided Molecular Design, has provided a clear answer. An industry-academia joint research team consisting of Professor Ioannis G. Karafyllidis from the Democritus University of Thrace in Greece and researchers from the multinational pharmaceutical company Pfizer conducted this innovative study. ■ Combination of an Extended Lattice Model and Grover's Quantum Search Algorithm The researchers significantly expanded the previously used protein lattice model to fully encompass hydrogen bonding and hydrophobic interactions, which are key interactions between proteins and ligands. Within this expanded model, they introduced quantum state labelling for each interaction site and implemented an extended and modified form of Grover's quantum search algorithm. Simulation of the algorithm demonstrated that it can identify potential docking sites inside the target protein even within a massive interaction space, and evaluate the optimal binding positions much more efficiently and rapidly than classical computing tools through Euclidean distance calculations based on the quantum SWAP test. ■ Real Quantum Hardware Verification and Infinite Scalability Notably, this study did not stop at simulators but verified the algorithm's accuracy by running it directly on IBM's real 127-qubit quantum computers (such as ibm_brisbane). To overcome the hardware noise generated during this process, they successfully applied state-of-the-art quantum error mitigation techniques such as M3 (Matrix-free Measurement Mitigation), Pauli twirling, and dynamical decoupling. The most powerful asset of the newly developed quantum algorithm is its exceptional scalability. Thanks to this characteristic, the algorithm is perfectly suited for exploring binding sites within complex target proteins with massive molecular weights. By breaking the bottleneck of traditional drug discovery pipelines that required heavy computations, it is expected to serve as a revolutionary milestone that will exponentially explode the potential of drug candidate screening and molecular design as the number of available qubits increases with future hardware advancements. #QuantumAlgorithm #DrugScreening #ProteinLigandDocking #GroverAlgorithm #QuantumComputing #DrugDevelopment #MolecularDocking #QuantumBiology #Biophysics #KoreanQuantumBiologySociety https://www.researchgate.net/publication/393436574_Quantum_algorithm_for_protein-ligand_docking_sites_identification_in_the_interaction_space
The drug discovery process has always been a problem for the pharmaceutical industry’s low rates of success, high expenses, and long-time frames. Quantum computing (QC) is being touted as a revolutionary advancement because of its unparalleled speed to carry out intricate multi molecular simulation and optimization. Unfortunately, its practical use has been suppressed due to the absence of proper hardware and the integration problems with traditional systems. Our solution is a quantum-classical pipeline for drug discovery. This pipeline utilizes machine learning (ML) for protein-ligand binding, drug property optimization, and even de novo drug design. In this paper we describe the pipeline, its components, the way it operates using NISQ devices, and the improvements it has in terms of accuracy and scalability (93.5% vs 78.2%) when compared with classical methods. Finally, we summarize how this can aid in modern drug discovery. It could significantly decrease the cost and timeline for pharmaceutical innovations.
Research Problem: The traditional methods of drug discovery are time-consuming, costly, and at times ineffective. There is a need for more novel approaches that can enhance the processes of discovering new drugs and developing them into usable products. Objective of the Paper: This paper aims to conduct a review of the literature and find how the application of quantum computing can change the way drugs are discovered and processed in practice. Process of Review: The review process involved a comprehensive examination of the available literature and recent advances in the application of quantum computing to drug discovery. The review encompassed major studies, theories, and case studies related to the subject matter, aiming to identify the current state and potential future directions of the domain. Insights of the Review: 1. Primary Building Blocks: With quantum computing, superposition, entanglement, and other principles can be utilised to enable complex computations to be performed at higher speeds using less time than traditional computers. 2. Quantum modelling: Quantum computers are expected to accurately model the interactions of various molecules, which could result in the identification of viable drug candidates. 3. Drug Discovery Processes: Quantum algorithms are capable of faster processing than traditional methods when it comes to solving optimisation problems, such as protein structure prediction and molecular docking, in drug design. 4. Limitations and Challenges: As great as the promise of quantum computing is, it has its limitations and challenges, including hardware limitations, error rates, and the need for specialised algorithms. 5. Future Developments: The ongoing development of quantum hardware and algorithms is expected to enhance the practical applications of quantum computing in drug discovery, enabling the quicker and more cost-effective creation of new drugs.